Phase II trial of ifosfamide in the treatment of metastatic hormone-refractory patients with prostatic cancer

Cancer Investigation

Volumn 8, Issue 5, 1990, Pages 477-481

  Mahjoubi, Monder ^a   Azab, Mohamed ^a   Ghosn, Marwane ^a   Theodore, Christine ^a   Droz, Jean Pierre ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IFOSFAMIDE; MESNA;

ADULT; AGED; ARTICLE; BRAIN DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER;

AGED; DRUG ADMINISTRATION SCHEDULE; HUMAN; IFOSFAMIDE; MALE; MESNA; MIDDLE AGE; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0025646733     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909009012071     Document Type: Article

References (13)

1. Cancer statistics
2. Long term survival after hormonal therapy for stage D prostate cancer
3. Chemotherapy of urologic malignancies
4. Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5 fluorouracil: results of first national randomized study
5. Results of trials of the USA national prostatic cancer project
6. An overview of chemotherapeutic trials in advanced cancer of the prostate
7. Cytotoxic agents effective in prostate cancer
8. The chemotherapy of prostatic adenocarcinoma
9. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma
10. Cyclophosphamide versus 5FU, doxorubicine and mitomycin C in the treatment of hormone resistant metastatic carcinoma of the prostate: A preliminary report of randomized trial
11. Weekly doxorabicin in endocrine refractory carcinoma of the prostate
12. Prostate cancer chemotherapy